JPX · 4519.T
Chugai Pharmaceutical Co., Ltd.
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
Loading market information…
JPX · 9987.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Suzuken Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 10.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Suzuken Co., Ltd.’s forward annual dividend is ¥120 per share, paid semi-annual. The forward yield is 4.01% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Suzuken Co., Ltd.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of ¥52. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Suzuken Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Suzuken Co., Ltd., along with its affiliated companies, operates primarily as a wholesale distributor of pharmaceuticals, serving both domestic and international markets. The company's diverse activities are organized into four distinct divisions. Its Pharmaceutical Distribution Business focuses on sourcing a wide array of products, including ethical drugs, diagnostic reagents, medical devices, and other health-related items directly from manufacturers, and then supplying these to healthcare institutions and pharmacies. The Pharmaceutical Manufacturing Business is dedicated to the research, development, production, and commercialization of prescription pharmaceuticals and diagnostic tools, with a particular emphasis on diabetes and kidney-related conditions. Through its Pharmacy Business segment, Suzuken offers services via family pharmacists, works to enhance the efficiency of local pharmacy operations, and provides educational support. The Healthcare-Related Services Business encompasses a variety of support functions, such as contract distribution for manufacturers, the distribution of orphan drugs, and nursing care services. This segment is also involved in the development, manufacturing, and sale of medical equipment, including electrocardiographs, blood pressure monitors, stethoscopes, general medical supplies, and health promotion devices. Furthermore, Suzuken Co., Ltd. publishes medical journals for healthcare professionals and collaborates with Bushu Pharmaceuticals Ltd. to provide specialized contract drug services. The company was established in 1932 and is headquartered in Nagoya, Japan.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:35 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 13, 2025 | ¥28+165.19% vs estimate | ¥562.18B-4.14% vs estimate |
|---|
| Q3 2025 | Feb 12, 2025 | ¥137+165.84% vs estimate | ¥641.35B+1.38% vs estimate |
|---|
| Q2 2025 | Nov 12, 2024 | ¥99+99.82% vs estimate | ¥615.13B+1.64% vs estimate |
|---|
KEEP COMPARING
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
¥3,441+¥67 (+1.99%)
MediPal Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.23% below the high.
¥2,469+¥29 (+1.19%)
Alfresa Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 8.06% below the high.
¥4,004+¥54 (+1.37%)
Toho Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 20.41% below the high.
¥2,576+¥27 (+1.06%)
AS ONE Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.75% below the high.
¥1,545+¥36 (+2.39%)
Vital KSK Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.54% below the high.
¥1,920+¥9 (+0.47%)
OLBA HEALTHCARE HOLDINGS, Inc.’s quoted price sits in the lower half of its reported 52-week range, 14.21% below the high.
¥737+¥6 (+0.82%)
Medius Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 16.63% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
